Core Viewpoint - The company, CloudTop New Medicine (01952.HK), has made significant progress in patent protection for its original product, Budesonide Enteric-Coated Capsules (Nai Fu Kang®), following a favorable ruling from the Guangzhou Intellectual Property Court [1] Group 1: Legal Developments - The Guangzhou Intellectual Property Court issued a civil ruling on February 26, 2026, fully supporting the company's pre-litigation preservation application [1] - The court ordered relevant generic drug companies to immediately cease infringement activities and stop listing their products [1] - The ruling is effective immediately upon issuance, reflecting the court's commitment to upholding intellectual property rights [1] Group 2: Company Commitment - The company expressed its welcome for the court's fair ruling and reiterated its commitment to legally protect intellectual property [1] - The company aims to promote innovative therapies to benefit more patients [1]

Core Viewpoint - Tianchen Biopharmaceuticals (Suzhou) Co., Ltd. has resubmitted its listing application on the Hong Kong Stock Exchange, with Guojin Securities (Hong Kong) as the sole sponsor, marking a renewed effort after its initial application lapsed in August 2025 [1][42]. Company Overview - Tianchen Biopharmaceuticals, founded in October 2020, focuses on the development of new drugs for allergic and autoimmune diseases [6][44]. - The company is co-founded by Dr. Liu Heng and Dr. Sun Naichao, both experienced in antibody drug development [8][49]. Development Milestones - Key milestones include: - 2020: Company established and initiated research on LP-003 [9][54]. - 2021: Completed Series A financing [10]. - 2022: LP-003 received approval for clinical trials for chronic spontaneous urticaria (CSU) [11][56]. - 2023: LP-003 approved for allergic rhinitis (AR) clinical trials, and LP-005 approved for paroxysmal nocturnal hemoglobinuria (PNH) clinical trials [13][59]. - 2024: Initiated Phase III clinical trials for LP-003 for seasonal AR and Phase II trials for CSU and allergic asthma [16][61]. - 2025: Completed multiple rounds of financing and prepared for listing [19][64]. Financial Performance - The company has reported significant losses, with cumulative losses of approximately 370 million RMB over two years and nine months, primarily due to high R&D expenditures [22][66]. - Specific losses reported include 95.78 million RMB in 2023, 137.32 million RMB in 2024, and 138 million RMB in the first nine months of 2025 [22][66]. Shareholder Structure - The company’s ownership structure has evolved through various financing rounds, with the founding team holding shares through an employee incentive platform [25][68]. - Major investors include Dongfang Fuhai, Qiming Venture Partners, and Honghui Capital, among others [25][72]. Leadership Team - The executive team includes: - Dr. Liu Heng, Chairman and CEO, responsible for overall strategy and operations [33][77]. - Dr. Sun Naichao, Executive Director, guiding the company's R&D strategy [33][78]. - Mr. Xie Ming, Executive Director and Deputy General Manager, overseeing strategic execution [33][78]. - The board includes representatives from major investment firms and independent directors to ensure governance and oversight [41][85].

Core Viewpoint - Zhongtai Securities maintains a "Buy" rating for HBM Pharmaceuticals (02142), projecting significant revenue and profit growth from the licensing agreement and milestone payments related to HBM7020 and HBM4003 [1] Group 1: Financial Projections - The company is expected to achieve total revenue of 1.4 billion, 1.594 billion, and 1.485 billion yuan for the years 2025 to 2027, an increase from previous estimates of 1.342 billion, 974 million, and 1.026 billion yuan [1] - Projected net profit attributable to the parent company is estimated at 665 million, 768 million, and 740 million yuan for the same period, up from previous estimates of 621 million, 307 million, and 432 million yuan [1] Group 2: Licensing Agreement - On February 23, 2026, HBM Pharmaceuticals announced a licensing and equity cooperation agreement with Solstice Oncology, granting exclusive development and commercialization rights for HBM4003 outside Greater China [1] - The agreement includes upfront payments totaling over 105 million USD, comprising a 50 million USD cash upfront payment, a 5 million USD near-term payment, and equity valued at over 50 million USD [1] - HBM Pharmaceuticals may also receive up to approximately 1.1 billion USD in milestone payments based on future specific events and tiered royalties based on net sales outside Greater China [1] Group 3: Product Characteristics - HBM4003 is the world's first fully human only heavy chain antibody entering clinical stages, targeting the CTLA-4 pathway, which has regained focus in immuno-oncology [2] - The product demonstrates enhanced antibody-dependent cellular cytotoxicity (ADCC) and high specificity in eliminating Treg cells expressing high levels of CTLA-4 in the tumor microenvironment [2] - Its unique mechanism of action shows potential for improved therapeutic efficacy while significantly reducing drug toxicity [2] Group 4: Clinical Trial Results - HBM4003 has shown good safety and strong efficacy in Phase I monotherapy trials, with potential indications including melanoma, non-small cell lung cancer, hepatocellular carcinoma, and neuroendocrine tumors [3] - Recent Phase II clinical data indicated positive efficacy in MSS colorectal cancer when combined with another treatment, achieving an overall response rate of 34.8% and a median progression-free survival of 4.2 months [3] - This performance is superior to existing CTLA-4 antibodies combined with PD-1 antibodies in treating advanced colorectal cancer, which typically shows progression-free survival of 2 to 3 months [3] Group 5: Cash Flow Impact - The upfront payment of over 105 million USD will directly enhance the company's cash flow [4] - This transaction, combined with the company's previous profit forecast for 2025 (estimated at 88 million to 95 million USD), will further solidify its robust cash flow [4] - The cumulative effects of multiple business development activities are expected to enhance the company's growth prospects in the medium term [4]

Core Viewpoint - Zhongtai Securities maintains a "Buy" rating for HBM Pharmaceuticals-B (02142), projecting revenue growth driven by licensing agreements and milestone payments from HBM7020 and HBM4003, with expected revenues of 1.4 billion, 1.594 billion, and 1.485 billion yuan from 2025 to 2027, and net profits of 666 million, 768 million, and 740 million yuan respectively [1] Group 1: Licensing Agreement and Financial Impact - On February 23, 2026, HBM Pharmaceuticals announced a licensing and equity cooperation agreement with Solstice Oncology, granting exclusive rights for HBM4003 outside Greater China, with upfront payments exceeding $105 million, including a $50 million upfront cash payment and $5 million in recent payments [1] - The agreement also includes potential milestone payments of up to $1.1 billion based on future development and regulatory achievements, along with tiered royalties based on net sales outside Greater China [1] Group 2: Product Characteristics and Clinical Potential - HBM4003 is the world's first fully human heavy-chain antibody targeting CTLA-4, showing enhanced antibody-dependent cellular cytotoxicity (ADCC) and high specificity for CTLA-4 expressing Treg cells in the tumor microenvironment, indicating potential for improved therapeutic efficacy and reduced toxicity [2] - In Phase I trials, HBM4003 demonstrated good safety and strong efficacy, with potential indications including melanoma, non-small cell lung cancer, hepatocellular carcinoma, and neuroendocrine tumors [3] Group 3: Cash Flow and Growth Outlook - The recent payment structure exceeding $105 million will directly enhance the company's cash flow, complementing previous profit forecasts of approximately $88 million to $95 million for 2025, thereby solidifying the company's financial stability and growth potential in the medium term [4]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative performance increase of over 15% against the benchmark index within the next 6 to 12 months [9] Core Insights - The company has entered into a licensing agreement with Solstice Oncology for the clinical-stage candidate HBM4003 (CTLA-4 antibody), which includes an upfront payment of over $105 million, enhancing the company's cash flow [5] - HBM4003 is the first fully human heavy-chain antibody to enter clinical trials globally, showing strong anti-tumor effects and a differentiated pharmacokinetic profile, with potential applications in various advanced solid tumors [5] - The company forecasts significant revenue growth, projecting total revenues of 1.4 billion, 1.594 billion, and 1.485 billion yuan for 2025, 2026, and 2027 respectively, alongside substantial net profit increases [5][3] Financial Projections - The company anticipates a revenue of 635 million yuan for 2023, followed by a decrease to 274 million yuan in 2024, and a rebound to 1.4 billion yuan in 2025, reflecting a year-on-year growth rate of 411% [3] - Net profit is expected to rise dramatically from 20 million yuan in 2024 to 665 million yuan in 2025, with a projected growth rate of 3,229% [3] - The earnings per share (EPS) is projected to increase from 0.02 yuan in 2024 to 0.74 yuan in 2025, and further to 0.86 yuan in 2026 [3][8] Valuation Metrics - The price-to-earnings (P/E) ratio is expected to decrease from 500.3 in 2024 to 15.0 in 2025, indicating improved valuation as earnings grow [3][8] - The price-to-book (P/B) ratio is projected to decline from 11.2 in 2024 to 4.7 in 2025, reflecting a more favorable valuation as the company matures [3][8]

Financial Data Summary - The company reported total revenue of 47.86 million RMB for the year 2025, representing a year-on-year increase of 89.80% [1][2] - The net loss attributable to the parent company was 157.94 million RMB, an increase in loss of 6.58 million RMB compared to the previous year [1][3] - The total assets at the end of the reporting period were 3.70 billion RMB, an increase of 248.65% from the beginning of the period [1][3] - The equity attributable to the parent company was 2.90 billion RMB, reflecting a growth of 381.75% [1][3] Operational Performance - The significant increase in total revenue was primarily driven by the rapid sales breakthrough of the new product "Aofumin," which was approved for market launch in July 2025 [2][3] - Continuous investment in research and development has been maintained to support the ongoing output of research results [2] Key Changes in Financial Metrics - The company's total assets, equity attributable to the parent company, share capital, and net asset value per share increased by 248.65%, 381.75%, 33.37%, and 261.61% respectively, mainly due to the funds raised from the initial public offering [3]

Financial Data and Indicators - The company reported total revenue of approximately 1,067.91 million yuan, representing a year-on-year increase of 26.18% [1][2] - The net profit attributable to the parent company was approximately 27.87 million yuan, marking a turnaround from a loss to profit compared to the same period last year [1][2] - The net profit attributable to the parent company, excluding non-recurring gains and losses, was approximately -92.50 million yuan [1] Operational Performance and Financial Condition - The company has implemented a development strategy focused on innovation and commercialization, leading to sustained revenue growth from its first quadrivalent meningococcal vaccine, Manhaixin [2] - Cost reduction and efficiency improvement measures have been effectively managed, contributing to enhanced overall profitability [2] - The company received government subsidies and international research funding, which were recognized as non-recurring gains during the reporting period [2] Changes in Key Financial Metrics - Operating profit, total profit, and net profit attributable to the parent company all achieved a turnaround from loss to profit year-on-year [3] - Basic earnings per share and weighted average return on net assets turned positive [3] - The net loss attributable to the parent company, excluding non-recurring gains and losses, narrowed year-on-year due to increased revenue and cost-saving measures [3]

Core Viewpoint - The company, Shengxiang Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for a clinical trial application to expand the indications of its product, Human Growth Hormone Injection (brand name: Haizhiyuan), to include idiopathic short stature (ISS) [1][3]. Group 1: Product Information - The product, Human Growth Hormone Injection (Haizhiyuan), is a water injection formulation developed based on Shengxiang Haiji's injectable human growth hormone, which was approved for market on November 7, 2023, for use in children with growth retardation due to endogenous growth hormone deficiency and those with short stature due to Noonan syndrome [2]. Group 2: Clinical Trial Approval - The clinical trial application for the new indication of ISS has been approved, allowing Shengxiang Haiji to initiate Phase III clinical trials to enhance clinical research data and expand application scenarios [1][3]. Group 3: Impact on the Company - The approval for the ISS indication is expected to optimize the company's business structure, improve strategic product line layout, and enhance core competitiveness [3]. - The company acknowledges the high investment, high risk, and high added value associated with biopharmaceutical products, noting that the clinical trial process is complex and subject to various uncertainties [3].

Financial Performance Summary - In 2025, the company achieved total operating revenue of 230.72 million yuan, representing a growth of 666.65% compared to the previous year [1] - The net profit attributable to the parent company was a loss of 536.22 million yuan, which is a 32.74% reduction in losses year-on-year [1][2] - The net profit attributable to the parent company after deducting non-recurring gains and losses was a loss of 579.22 million yuan, with a 27.99% reduction in losses compared to the previous year [1] Asset and Equity Status - As of the end of the reporting period, the company's total assets amounted to 2.99 billion yuan, a decrease of 4.87% from the same period last year [2] - The equity attributable to the parent company was 1.58 billion yuan, down 25.49% year-on-year [2] Revenue and Profit Analysis - The significant increase in operating revenue is attributed to the expansion of the sales market for the company's first commercialized product, the Saliqi monoclonal antibody injection, which saw steady growth in sales [2] - The revenue from the licensing and commercialization agreement for the GR1803 injection also positively impacted the company's net profit during the reporting period [2] Drug Development Update - The company announced that its GR1802 injection for adult seasonal allergic rhinitis has passed the primary endpoint in Phase III clinical trials and the new drug application has been accepted by the National Medical Products Administration (NMPA) [4][5] - GR1802 is a fully human anti-IL-4Rα monoclonal antibody that specifically binds to the IL-4Rα on cell surfaces, inhibiting Th2-type inflammatory responses [6] Clinical Trials and Future Prospects - The GR1802 injection has multiple indications in clinical trials, including chronic rhinosinusitis with nasal polyps and chronic spontaneous urticaria, with various stages of clinical trials ongoing [6] - As of the announcement date, only two other drugs targeting the same receptor have been approved for marketing in China [7]

Financial Data and Key Metrics Changes - Total revenue for 2025 grew 29% to $96 million, landing at the high end of guidance, which was raised twice in the second half of the year [5][13] - Adjusted EBITDA increased to $25 million or 26% of revenue, up from $13 million or 18% in 2024 [5][18] - Adjusted net income for Q4 was $1.9 million, compared to an adjusted net loss of $0.1 million in Q4 of the prior year [17] Business Line Data and Key Metrics Changes - In Q4, total revenue reached $24.8 million, increasing 20% year-over-year, primarily driven by the biopreservation media (BPM) franchise [6][13] - BPM product line accounted for approximately 85% of total revenue, with commercial BPM customers accounting for nearly 50% of revenue, up from the low 40s range in 2024 [6][14] - The hPL media business was flat year-over-year due to import restrictions in China, which have since been lifted [14] Market Data and Key Metrics Changes - BioLife's BPM products are embedded in 16 approved therapies and utilized in over 250 commercially sponsored CGT trials in the U.S., representing over 70% market share [7] - Anticipation of up to 5 unique therapy approvals over the next 12 months, along with 1 new indication and at least 1 geographic expansion [9] Company Strategy and Development Direction - The company aims to drive sustainable, profitable growth and shareholder value with a streamlined portfolio centered on market-leading consumables [4] - A strategic distribution and product development agreement with Qkine Limited was established to expand the product offering into cytokines, complementing the emerging hPL product line [10][11] - The company is focused on increasing adoption of non-BPM products and driving operational excellence across the organization [71] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term trajectory of the cell and gene therapy (CGT) market, supported by favorable regulatory developments and increased strategic investments by large pharma [12] - For 2026, the company issued guidance of total revenue between $112 million and $115 million, reflecting growth of 17%-20% [11][20] - Expected full year positive GAAP net income for the first time in many years, along with further expansion of adjusted EBITDA margins compared to 2025 [21] Other Important Information - The company implemented ERP manufacturing modules in February 2026, enhancing automated processes and controls for manufacturing and accounting functions [13] - Cash and marketable securities balance at December 31, 2025, was $120.2 million, an increase from $105.4 million at December 31, 2024 [19] Q&A Session Summary Question: Guidance assumptions between commercial and clinical - Management expects commercial customers to represent 50%-55% of revenue in 2026, with no significant uptick seen in clinical activity levels yet [25][26] Question: Bag yield impact on margins - The bag yield issue was about a 2 to 3-point headwind on gross margin in the second half of 2025, with solutions expected to be implemented by Q4 2026 [26][27] Question: Exposure to CAR T market - Over 80% of commercial exposure is related to CAR T therapies, with patient access being a key constraint to overall adoption [32] Question: Cross-selling initiative success - The growth rate of non-BPM tools is expected to outpace BPM, with metrics on customer usage of multiple products being a future goal [40][41] Question: Qkine partnership details - The partnership with Qkine is seen as a long-term strategic move, with revenue expected to materialize in the future [46][47]